Experimental Injection Reduces LDL Cholesterol by 66% with a Single Dose
Eli Lilly Gene-Editing Therapy Shows Significant Cholesterol Reduction in Early Clinical Trials Eli Lilly and Company has reported promising early results from a clinical trial involving a gene-editing therapy designed to lower cholesterol levels. In a high-dose study, the experimental treatment reduced cholesterol by approximately 62%, marking a potential shift toward long-term, single-dose solutions for … Read more
